Page 11 - PACE: Advanced Prostate Cancer Consensus
P. 11
Natural History of Prostate Cancer
de novo ARCHES (enzalutamide)
CHAARTED (docetaxel)
mets ENZAMET (enzalutamide)
GETUG-AFU 15 (docetaxel)
LATITUDE (abiraterone*)
Metastatic STAMPEDE (abiraterone*)
TITAN (apalutamide)
CSPC
(mCSPC)
Localized Metastatic
prostate CRPC
cancer (mCRPC)
Non- Non- TAX327 (docetaxel)
metastatic metastatic COU-AA-301 (abiraterone*)
COU-AA-302 (abiraterone*)
CSPC CRPC PROSPER (enzalutamide) PREVAIL (enzalutamide)
SPARTAN (apalutamide)
AFFIRM (enzalutamide)
(nmCRPC) ARAMIS (darolutamide) TROPIC (cabazitaxel*)
ALSYMPCA (radium-223)
*Treatment included prednisone
mCRPC, metastatic castration-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; mets, metastases;
nmCRPC, non-metastatic castration-resistant prostate cancer
Adapted from Aggarwal RR, et al. Oncology (Williston Park) 2017;31:467-474.
